PLENARY LECTURES

PL1: Tissue specific regulation of heme biosynthesis
Barry PAW (USA)

PL2 : Cellular transport, trafficking, and recycling of heme
Iqbal HAMZA (USA)

PL3 : Acute Intermittent Porphyria, pathophysiology of acute attacks and recurrency, treatment options, overview and update
Robert J. DESNICK (USA)

PL4 : Results from Clinical Trial using ALN-AS1, an Investigational RNAi Therapeutic Targeting ALAS1 for the Treatment of Acute Hepatic Porphyrias (ALNYLAM)
Eliane SARDH (Sweden) (for EU/USA Porphyria Reference Centers)

PL5 :  Variegate Porphyria, update on pathophysiology and management of cutaneous symptoms
Peter MEISSNER (SA)

PL6 : Clinical aspects, pathophysiology and management of PCT
Jorge FRANK (Germany)

PL7 : Pharmacological chaperones as a potential therapy for congenital erythropoietic porphyria
Oscar MILLET (SP)

PL8 : Splice modulating therapy in EPP, state of the art
Laurent GOUYA (France)

PL9 : Afamelanotide for the treatment of protoporphyria-induced phototoxicity, where are we ?
Janneke LANGENDONK (Netherlands)

PL11 :  Porphyria associated kidney disease
Nicolas PALLET (France)

PL12 : Porphyria associated liver disease
Staffan WAHLIN (Sweden)

PL13 : The value of long term longitudinal clinical and laboratory observations in porphyria follow up
Karl ANDERSON (USA)

PL14 : Measurement of therapeutic effect in the porphyrias: Balancing the needs of professionals, patients and the pharmaceutical industry
Elisabeth MINDER (Switzerland)

PL15 : Diagnosing and monitoring porphyrias : benefits and disadvantages of centralizing porphyria dedicated laboratory tests
Sverre SANDBERG (Norway)

PL16 : EPNET and EMQN EQAS impact on porphyria diagnosis
Sharon WAHTLEY (UK) and Aasne AARSAND (Norway)

PL17 : Gene correction in erythropoietic porphyrias by the CRISPR/Cas9 technology
François MOREAU-GAUDRY (France)

PL18 : Inducing iron deficiency improves erythropoiesis and photosensitivity in CEP
John PHILIPS (USA)